Login to Your Account


Gilead golden in HCV for now but many others in the wings

By Marie Powers
Staff Writer

Monday, February 3, 2014

Anyone who thought Gilead Sciences Inc. had the hepatitis C virus (HCV) market sewn up with the December 2013 FDA approval of once-daily oral nucleotide analogue sofosbuvir, branded Sovaldi, isn’t taking the long view. Sovaldi is off to a roaring start but, as Leerink Partners LLC analyst Howard Liang observed in a recent HCV industry update, “by our count there are a total of 19 interferon (IFN)-free regimens for which some sustained virological response (SVR, viral cure) data are available.”

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription